文献速递胃肠动力与功能性疾病

5-HTT LPR与GNβ3 825C>T基因多态性与功能性消化不良抗抑郁治疗反应:功能性消化不良治疗试验研究

Polymorphisms of 5-HTT LPR and GNβ3 825C>T and Response to Antidepressant Treatment in Functional Dyspepsia: A Study from The Functional Dyspepsia Treatment Trial.
PubMed 文献 · Am J Gastroenterol · 2017-03-14

功能性消化不良治疗试验的二次分析,256例(GNβ3 825C>T)和246例(5-HTT LPR)患者随机接受安慰剂、阿米替林50 mg或艾司西酞普兰10 mg,主要终点为末10周中至少5周获得充分缓解。两种基因多态性均不影响治疗反应(P=0.89和P=0.54)。

要点

  • GNβ3 825C>T与5-HTT LPR多态性均不影响功能性消化不良患者对三环类或SSRI抗抑郁药的治疗反应。
  • 艾司西酞普兰组中SS/LS基因型较LL基因型有更 favorable 反应倾向(40% vs 31%),但未达统计学显著(P=0.43)。
  • 两种多态性均符合Hardy-Weinberg平衡。

核心结论

  • GNβ3 825C>T和5-HTT LPR遗传变异不改变功能性消化不良患者对三环类和SSRI抗抑郁药的治疗反应。

研究设计与样本

  • 功能性消化不良治疗试验的基因多态性分析,参与者随机接受安慰剂、阿米替林50 mg或艾司西酞普兰10 mg。
  • GNβ3 825C>T基因分型数据 available for 256例(88%),5-HTT LPR基因分型数据 available for 246例(84%)。
  • 主要终点为末10周中至少5周获得充分缓解。

主要发现

  • 5-HTT LPR和GNβ3 825C>T基因型均不影响治疗反应(P=0.89和P=0.54)。
  • 艾司西酞普兰治疗组中,SS/LS基因型较LL基因型有更 favorable 的充分缓解倾向(40% vs 31%),但未达统计学显著(P=0.43)。
  • 两种多态性均处于Hardy-Weinberg平衡。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The Functional Dyspepsia Treatment Trial reported that amitriptyline (AMI) was associated with adequate relief of functional dyspepsia (FD) symptoms, but the pharmacogenetics of antidepressant response in FD are not known. GNβ3 825C>T CC genotype has been previously linked to FD and TT genotype to antidepressant response in depression. The ss genotype of the 5-HTT LPR variant of the serotonin transporter gene (SLC6A4) has been linked to selective serotonin reuptake inhibitor (SSRI) response. We aimed to examine whether GNβ3 825C>T and 5-HTT LPR polymorphisms result in differential treatment effects in FD patients receiving antidepressant therapy. METHODS: Participants were randomized to receive placebo, 50 mg AMI, or 10 mg escitalopram (ESC). The primary end point was adequate relief for ≥5 weeks of the last 10 weeks. Genotyping of GNβ3 825C>T and 5-HTT LPR was performed utilizing PCR-based methods. RESULTS: GNβ3 825C>T and 5-HTT LPR genotype data were available for 256 (88%) and 246 (84%) patients, respectively. Both polymorphisms were in Hardy-Weinberg equilibrium. In tests for differential treatment, neither 5-HTT LPR nor GNβ3 825C>T genotype influenced response to therapy (P=0.89 and P=0.54, respectively). Although there was a tendency for a more favorable response to ESC in the SS/LS genotype compared to the LL genotype groups (40% vs. 31% reporting adequate relief of FD symptoms) among those in the ESC treatment arm, this was not significant (P=0.43). CONCLUSIONS: GNβ3 825C>T and 5-HTT LPR genetic variants do not alter treatment response to tricyclic and SSRI antidepressants in FD.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Saito YA, Locke GR, Almazar AE, et al. Polymorphisms of 5-HTT LPR and GNβ3 825C>T and Response to Antidepressant Treatment in Functional Dyspepsia: A Study from The Functional Dyspepsia Treatment Trial. Am J Gastroenterol. 2017. PMID: 28291238. doi:10.1038/ajg.2017.52

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。